Premium
Amifostine for children with medulloblastoma treated with cisplatin‐based chemotherapy
Author(s) -
Fisher Michael J.,
Lange Beverly J.,
Needle Michael N.,
Janss Anna J.,
Shu HuiKuo G.,
Adamson Peter C.,
Phillips Peter C.
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20132
Subject(s) - amifostine , ototoxicity , medicine , medulloblastoma , cisplatin , lomustine , chemotherapy , radiation therapy , oncology , vincristine , cyclophosphamide , pathology
In adult patients, amifostine appears to ameliorate cisplatin‐related nephrotoxicity and ototoxicity. We assessed the safety and efficacy of amifostine in 11 children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor treated with radiotherapy and vincristine, lomustine, and cisplatin. Amifostine was administered immediately prior to and 4 hr into the cisplatin infusion. Amifostine caused assymptomatic hypotension and hypocalcemia in 18 and 82% of patients, respectively. Despite amifostine use, 78% of patients developed significant ototoxicity. Although relatively well tolerated, amifostine does not appear to have a major impact on ameliorating the risk of developing significant nephro‐ and ototoxicity in children with medulloblastoma. Larger studies will help clarify these findings. Pediatr Blood Cancer 2004;43:780–784. © 2004 Wiley‐Liss, Inc.